Business
Apnimed Raises $192M in IPO for What Could Be the First Oral Sleep Apnea Drug
Shares jumped 56% on debut as the biotech advances oxnimbi, a once-nightly pill targeting an underlying cause of obstructive sleep apnea, toward a 2027 FDA decision.